Latest Litigation News

Acusensus Limited reported a robust 40% increase in revenue to $40.3 million for the half-year ended December 2025, driven by new contracts and international growth. However, the company recorded a substantial $20.8 million loss, largely due to a $16 million litigation settlement and strategic investments in future growth.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

DUG Technology’s US subsidiary has been ordered to pay over US$2 million following a breach of contract ruling, but the company is gearing up to contest the judgment through appeals.

Light & Wonder, Inc. reported robust full-year 2025 financial results, highlighted by record revenues, strong cash flow growth, and a major litigation settlement. The company also completed its transition to a sole ASX listing and returned $877 million to shareholders through share repurchases.

Pacific Current Group reported a net loss for the half-year ending December 2025, driven by significant non-cash impairments and disposals, while repaying its senior secured debt and declaring a fully franked interim dividend.

London City Equities Limited reported a 38% revenue increase and a $5.6 million capital gain from asset sales, while boosting liquidity to nearly 60% of its portfolio and raising dividends amid a cautious investment outlook.

Transurban Group has reported a robust turnaround in its half-year results to December 2025, with revenue rising 8.1% and profit rebounding from a loss to $343 million. Major infrastructure projects like Melbourne’s West Gate Tunnel and Sydney’s M7-M12 integration are driving growth and operational momentum.

Medibank Private Limited reported a 6% rise in operating profit for the half-year ended December 2025, despite an 11% drop in net profit after tax amid ongoing cybercrime-related costs and legal challenges. The company also raised its interim dividend by 6.4%, signalling confidence in its capital position and growth strategy.

Solvar Limited reported a 5.8% rise in half-year NPAT to $20 million, driven by the sale of its New Zealand written-off loan book and expanded debt facilities. The company also announced a special dividend and outlined growth plans in commercial lending.

Mayne Pharma has initiated legal proceedings against Cosette Pharmaceuticals and associated parties, seeking substantial damages following the collapse of their acquisition deal.

Fletcher Building reports a stable half-year performance despite subdued markets, advancing its strategic pivot with the announced sale of its Construction division.

Neometals Ltd has resolved a longstanding legal dispute with a $1 million settlement, clearing the way to focus on advancing its Barrambie Gold Project and sustainable processing technologies.